Alexion Archives - Page 2 of 7 -

The European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the

Another hurdle down as EU clears AstraZeneca’s Alexion takeover

https://pharmaphorum.com/news/another-hurdle-down-as-eu-clears-astrazenecas-alexion-takeover/

News/ News/ R&D

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

Phil Taylor Alexion, complement therapeutics, EHA 2021, Haematology, iptacopan, Novartis, rare disease, Soliris, Ultomiris 0 Comment

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris,

EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH

https://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/

News/ News/ Sales and Marketing

UK competition watchdog probes AstraZeneca, Alexion merger

Phil Taylor Alexion, AstraZeneca, competition law, M&A, UK 0 Comment

The antitrust authority in the UK has launched an investigation into the proposed $39 billion takeover of US

UK competition watchdog probes AstraZeneca, Alexion merger

https://pharmaphorum.com/news/uk-competition-watchdog-probes-astrazeneca-alexion-merger/

Market Access/ News/ News

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

Phil Taylor Alexion, Apellis Pharma, AstraZeneca, Empaveli, rare disease, Soliris, Ultomiris 0 Comment

Apellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal

Apellis set to take on Alexion as FDA clears PNH drug Empaveli

https://pharmaphorum.com/news/apellis-set-to-take-on-alexion-as-fda-clears-pnh-drug-empaveli/

Market Access/ News/ News

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

Phil Taylor Alexion, AstraZeneca, Health Technology Assessment, HEOR, nephrology, NHS, rare disease, Scotland, Soliris, Ultomiris 0 Comment

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

https://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/

News/ News/ R&D

AZ posts solid Q1 results as Alexion merger looms

Richard Staines Alexion, AstraZeneca, M&A, Q1 0 Comment

AstraZeneca’s not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the

AZ posts solid Q1 results as Alexion merger looms

https://pharmaphorum.com/news/az-posts-solid-q1-results-as-alexion-merger-looms/

Market Access/ News/ News

CHMP backs Roche’s Enspryng for rare nerve disease NMOSD

Phil Taylor Alexion, CHMP, enspryng, EU, neurology, rare disease, Roche, Soliris 0 Comment

Roche’s Enspryng has been recommended for approval in the EU for treating neuromyelitis optica spectrum disorder (NMOSD), extending

CHMP backs Roche’s Enspryng for rare nerve disease NMOSD

https://pharmaphorum.com/news/chmp-backs-roches-enspryng-for-rare-nerve-disease-nmosd/

Market Access/ News/ News

NICE recommends Alexion’s long-acting Ultomiris for PNH

Richard Staines Alexion, AstraZeneca, market access, NICE 0 Comment

NICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft

NICE recommends Alexion’s long-acting Ultomiris for PNH

https://pharmaphorum.com/news/nice-recommends-alexions-long-acting-ultomiris-for-pnh/

Sales and Marketing/ Views & Analysis/ Views and analysis

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

Paul Tunnah Alexion, EU Leaders, Rare diseases 0 Comment

Alexion’s senior vice president of its international business talks to Paul Tunnah about the importance of “people-centred and

Alexion’s Camilla Harder Hartvig on making the impossible possible in rare disease

https://pharmaphorum.com/views-and-analysis/alexions-camilla-harder-hartvig-on-rare-diseases/

Trending

Alexion

Login